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AbstrACt
Objective The objective of the present study was to 
investigate associations of both overt and subclinical 
thyroid dysfunction with common ECG parameters in a 
large primary healthcare population.
Design Cross-sectional study.
setting and participants The study population 
comprised of primary healthcare patients in Copenhagen, 
Denmark, who had a thyroid function test and an ECG 
recorded within 7 days of each other between 2001 and 
2011.
Data sources The Danish National Patient Registry 
was used to collect information regarding baseline 
characteristics and important comorbidities.
Outcome measure and study groups Common ECG 
parameters were determined using Marquette 12SL 
software and were compared between the study groups. 
The study population was divided into five groups based 
on their thyroid status. Euthyroid subjects served as the 
reference group in all analyses.
results A total of 132 707 patients (age 52±17 years; 
50% female) were included. Hyperthyroidism was 
significantly associated with higher heart rate and 
prolonged QTc interval with significant interaction with age 
(p<0.009) and sex (p<0.001). These associations were 
less pronounced for patients with higher age. Subclinical 
hyperthyroidism was associated with higher heart rate 
among females, and a similar trend was observed among 
males. Hypothyroidism was associated with slower heart 
rate and shorter QTc but only in women. Moreover, longer 
P-wave duration, longer PR interval and low voltage 
were observed in patients with both subclinical and overt 
hypothyroidism. However, the presence of low voltage was 
less pronounced with higher age (p=0.001).
Conclusion Both overt and subclinical thyroid disorders 
were associated with significant changes in important ECG 
parameters. Age and gender have significant impact on the 
association of thyroid dysfunction particularly on heart rate 
and QTc interval.
IntrODuCtIOn
Overt and subclinical thyroid dysfunction is 
frequently observed in the general popula-
tion, especially in the elderly,1 2 and is closely 
linked with the cardiovascular system and 
affects the haemodynamics, cardiac mass, 
cardiac contractility and autonomic control 
of the cardiovascular system.3 Thyroid 
dysfunction has been widely demonstrated 
to be associated with various cardiovascular 
disorders and is associated with increased 
all-cause mortality, increased cardiovascular 
mortality as well as morbidity.4–6 Subclinical 
thyroid dysfunction is defined as abnormal 
thyroid-stimulating hormone (TSH) values 
with thyroxine (T4) and triiodothyronine 
(T3) levels within the normal range. Even 
these minor changes in the thyroid function 
in subclinical thyroid dysfunction are asso-
ciated with various kinds of cardiovascular 
strengths and limitations of this study
 ► This is the largest study (n=132 707) so far investi-
gating the effect of thyroid dysfunction on the ECG.
 ► Study subjects are categorised into clinical groups 
of thyroid dysfunctions making the interpretation 
and use of the study results easier in routine clinics.
 ► The study population is from the greater Copenhagen 
area that consists mainly of Caucasian people; 
therefore, extrapolation of the findings to other eth-
nic groups should be done carefully.
 ► Since no uniform selection criteria were applied and 
subjects were referred for thyroid function test and 
ECG based on the discretion of the general practi-
tioner, some selection bias cannot be ruled out.
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disorders, such as heart failure,7 atrial fibrillation4 8 and 
coronary artery disease.9 
Various ECG changes are associated to the spectrum of 
thyroid dysfunction,10 11 and they are potentially critical as 
even subtle ECG changes have prognostic importance.12 13 
Important ECG changes described in hypothyroidism are 
sinus bradycardia, prolonged QTc interval, changes in 
the morphology of the T-wave, QRS duration and low 
voltage.10 11 14 15 Similarly, hyperthyroidism is associated 
with increased incidence of atrial arrhythmias and changes 
in the QT interval.4 11 16 17 However, most of these conclu-
sions of ECG changes are based on studies with small-size 
population. Thus far, only two studies have investigated 
the ECG changes that occur in thyroid dysfunction in 
moderately large-scale population studies.10 17 However, 
instead of assigning the population into thyroid dysfunc-
tion group, both these studies investigated the direct 
association of either TSH or T4 with the ECG parameters, 
which makes it difficult to interpret in a clinical context. 
The aim of this study was to investigate associations of 
overt and subclinical stages of thyroid dysfunction to 
important ECG parameter changes in a large primary 
care population.
MethODs
study population
The study population consisted of primary care patients, 
who were referred for thyroid function testing and digital 
ECG recording at the Copenhagen General Practitioners 
Laboratory (CGPL) between 2001 and 2011. The CGPL is 
a biochemistry laboratory, to which general practitioners 
refer patients for investigations from the greater Copen-
hagen area in Denmark. The centralised laboratory 
ensures standardised procedures for the clinical tests. 
Data on serum TSH, free T4 (FT4) and total T4 were 
determined by the commercially available ADVIA Centaur 
equipment (Bayer/Siemens, Tarrytown, New York, USA). 
The same ADVIA centaur system from Siemens was used 
throughout the study period, and all assays were routinely 
subjected to external control for reliability. The intra-
assay coefficient of variation: <10% for all (TSH, FT4 and 
total T4). Subjects were included if they had a thyroid 
function test (TFT) and a concomitant ECG recorded 
within duration of ±7 days. Subjects with age <16 years 
or having an ECG unsuitable for measurement of chosen 
ECG parameters were excluded (figure 1).
Figure 1 Patient inclusion flow chart. Flow-chart showing the details of the inclusion process of patients for the 
study. TSH, thyroid-stimulating hormone.
Table 1 Definitions of thyroid disease and thyroid 
dysfunction levels
Thyroid 
dysfunction 
definitions TSH FT4 T4T
Overt 
hyperthyroidism
<0.2 mU/L >22 pmol/L >140 nmol/L
Subclinical 
hyperthyroidism
<0.2 mU/L 9–22 pmol/L 60–
140 nmol/L
Euthyroidism 0.2–5.0 mU/L 9–22 pmol/L 60–
140 nmol/L
Subclinical 
hypothyroidism
>5.0 mU/L 9–22 pmol/L 60–
140 nmol/L
Overt 
hypothyroidism
>5.0 mU/L <9 pmol/L <60 nmol/L
FT4, free thyroxine; T4T, total thyroxine; TSH, thyroid-
stimulating hormone. 
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The study population’s baseline characteristics, 
including comorbidities, were obtained from the Danish 
National Patient Registry that contains information on 
outpatient and hospital contacts where every diagnosis—
primary and secondary—are coded based on the WHO’s 
International Classification of Diseases (ICD).18 The diag-
noses obtained from this registry has previously been 
validated and has a high positive predictive value.19 ICD 
codes used for the classification of various comorbidities 
are provided in online supplementary appendix A.
The Information regarding concomitant medica-
tion therapy was obtained from The Danish Register 
of Medicinal Product Statistics (online supplementary 
appendix B), which holds data on all prescriptions 
from pharmacies in Denmark coded according to 
the international Anatomical Therapeutic Chemical 
Table 2 Baseline characteristics of study cohort
Variable
Overt 
hyperthyroidism 
(n=821)
Subclinical 
hyperthyroidism 
(n=1452)
Euthyroidism 
(n=127 215)
Subclinical 
hypothyroidism 
(n=2883)
Overt 
hypothyroidism 
(n=336)
Age (years) 54.0 (18.2) 64.3 (16.4) 52.2 (16.8) 58.4 (16.7) 57.7 (16.1)
Sex (men) 177 (21.6) 386 (26.6) 64 867 (51.0) 692 (24.0) 89 (26.5)
Thyroid function status
TSH (mU/L) 0.0 (0.0) 0.1 (0.1) 1.6 (0.9) 9.5 (8.3) 64.3 (43.0)
Free T4 (pmol/L) 42.2 (23.6) 17.2 (2.6) 15.4 (2.3) 13.4 (2.2) 6.1 (1.9)
Total T4 (pmol/L) 200.0 (63.0) 111.2 (19.4) 105.5 (21.7) 91.7 (17.9) 39.7 (16.9)
Comorbidity (%)
PVD 9 (1.1) 24 (1.7) 992 (0.8) 28 (1.0) ≤3*
Heart failure 12 (1.5) 22 (1.5) 1012 (0.8) 37 (1.3) 4 (1.2)
Ischaemic heart disease 18 (2.2) 60 (4.1) 3295 (2.6) 88 (3.1) 12 (3.6)
MI 10 (1.2) 22 (1.5) 1238 (1.0) 36 (1.2) 4 (1.2)
AF 10 (1.2) 25 (1.7) 1057 (0.8) 32 (1.1) ≤3
Arrhythmias 9 (1.1) 13 (0.9) 1029 (0.8) 32 (1.1) ≤3
CVD 15 (1.8) 64 (4.4) 2281 (1.8) 51 (1.8) 10 (3.0)
Malignancy 38 (4.6) 59 (4.1) 3301 (2.6) 113 (3.9) 13 (3.9)
Chronic renal failure ≤3 ≤3 109 (0.1) 4 (0.1) 0 (0.0)
Diabetes 32 (3.9) 69 (4.8) 3663 (2.9) 87 (3.0) 10 (3.0)
COPD 23 (2.8) 54 (3.7) 2089 (1.6) 52 (1.8) 8 (2.4)
Rheumatic disease 6 (0.7) 16 (1.1) 686 (0.5) 30 (1.0) ≤3
Drugs (%)
Lithium 0 (0.0) ≤3 210 (0.2) 9 (0.3) ≤3
Glucocorticoids 18 (2.2) 56 (3.9) 2058 (1.6) 48 (1.7) 7 (2.1)
QTc-prolonging drugs 108 (13.2) 270 (18.6) 18 249 (14.3) 447 (15.5) 51 (15.2)
Sotalol ≤3 ≤3 204 (0.2) 5 (0.2) 0 (0.0)
Digoxin 9 (1.1) 21 (1.4) 592 (0.5) 27 (0.9) ≤3
Amiodarone ≤3 ≤3 14 (0.0) ≤3 0 (0.0)
Warfarin 4 (0.5) 11 (0.8) 558 (0.4) 12 (0.4) 0 (0.0)
Beta-blockers 67 (8.2) 112 (7.7) 7543 (5.9) 221 (7.7) 15 (4.5)
Calcium antagonist 33 (4.0) 137 (9.4) 7528 (5.9) 222 (7.7) 19 (5.7)
ACE inhibitors or ARB 47 (5.7) 174 (12.0) 10 823 (8.5) 263 (9.1) 33 (9.8)
Thiazides 74 (9.0) 209 (14.4) 9633 (7.6) 328 (11.4) 41 (12.2)
Spironolactone 5 (0.6) 13 (0.9) 577 (0.5) 20 (0.7) ≤3
Loop diuretics 38 (4.6) 100 (6.9) 3091 (2.4) 131 (4.5) 11 (3.3)
*Numbers less than 3 are not reported.
AF, atrial fibrillation or atrial flutter; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary  disease; CVD, 
cardiovascular disease; MI, myocardial infarction; PVD, peripheral vascular disease; T4, thyroxine; TSH, thyroid-stimulating hormone. 
 on 25 June 2019 by guest. P
rotected by copyright.
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2018-023854 on 21 June 2019. D
ow
nloaded from
 
4 Tayal B, et al. BMJ Open 2019;9:e023854. doi:10.1136/bmjopen-2018-023854
Open access 
classification.20 All medication reported to influ-
ence thyroid function5 and ECG findings12 21 22 were 
included in the present study.
study groups
Patients were divided into five study groups based on 
TSH, free T3 and free T4 levels summarised in table 1. 
T3-thyrotoxicosis was defined as low TSH with normal T4 
but elevated T3.
electrocardiography
At the CGPL, digital ECGs were recorded by trained tech-
nicians according to a standardised protocol and were 
stored in the MUSE Cardiology Information system (GE 
Healthcare, Wauwatosa, Wisconsin, USA). The digital 
ECGs were processed using version 21 of the Marquette 
12SL algorithm. Using the 12SL algorithm, the following 
ECG parameters were measured: P-wave duration, 
PR interval, QRS duration and QTc interval (Bazett’s 
formula, QTcBaz=QT (ms)/[RR interval (ms)/1000]
1/2). 
P-wave duration, PR interval and QRS duration were 
adjusted for the heart rate. Low voltage was defined as a 
net QRS voltage <500 µV in all limb leads and/or <1000 
µV in precordial leads. We have previously described in 
detail about how the 12SL software is used to measure 
the various ECG parameters as well as validated these 
measurements.12
Only subjects having sinus rhythm on the analysed ECG 
were included; those with any kind of tachyarrhythmia—
supraventricular or ventricular—were excluded to 
study the influence of thyroid dysfunction on ECG 
measurements. Furthermore, subjects were excluded if 
they had any of the following ECG findings: all atrio-ventric-
ular (AV) blocks except first degree blocks, pace rhythms, 
bundle branch blocks (QRS interval >120 ms), multiple 
premature ventricular complexes or supraventricular 
complexes, delta waves, poor quality ECGs and intervals 
of interest below the 0.25th percentile and above the 
99.75th percentile of the study population. This filtering 
step has previously been validated to exclude ECGs 
unsuitable for measurement12 21 22 (figure 1).
statistical analyses
Continuous variables were presented as their mean±SD 
and compared using analysis of variance, and categorical 
variables were presented as counts and percentages and 
compared using χ2 test. For all comparison purposes, the 
euthyroid group was used as the reference group. Multiple 
linear regression analysis was performed using important 
ECG parameters—P-wave duration, PR interval, QRS 
duration, QTc interval (Bazett) and heart rate—as depen-
dent variables and the five thyroid status groups as inde-
pendent categorical variables. All models were adjusted 
for age and sex. In addition, P-wave duration, PR interval 
and QRS duration were all adjusted for heart rate. All 
ECG parameters were normally distributed and model 
assumptions were fulfilled. Multiple logistic regression 
analysis was used to assess the association between thyroid 
status and low voltage on ECG adjusting for age, sex and 
heart rate. For each analysis, tests for interaction were 
performed. An interaction was considered significant 
Figure 2 Mean ECG changes with thyroid dysfunction. Violin plots demonstrating the changes in the ECG parameters with 
thyroid dysfunction. The white box in the middle indicates the mean value and the red line indicates the trend with the changes 
in the thyroid status. The central blue area demonstrates the distribution of the individual parameters.
 on 25 June 2019 by guest. P
rotected by copyright.
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2018-023854 on 21 June 2019. D
ow
nloaded from
 
5Tayal B, et al. BMJ Open 2019;9:e023854. doi:10.1136/bmjopen-2018-023854
Open access
with a p value of less than 0.01. When an interaction with 
age was identified, population was stratified into groups 
using the tertile values as cut-offs (age groups: 16.0–44.6 
years, 44.6–60.0 years and 60.0–102.7 years).
We further performed sensitivity analyses, in which we 
excluded cardiac comorbidities (cardiac arrhythmias, 
ischaemic heart disease and congestive heart failure), as 
well as cardiac medications that are known to impact ECG 
parameters, such as QTc-prolonging drugs, class I and III 
antiarrhythmic drugs, digoxin, beta-blockers. The impact 
of TSH levels on heart rate and QTc interval was exam-
ined in additional analyses where TSH was included as 
a continuous variable in linear regression models using 
b-splines. These analyses were stratified according to age 
and sex as mentioned above. A two-tailed p value <0.05 
was considered statistically significant in all analyses. Data 
management and analyses were performed using SAS V.9 
and R V.3.4.1.
Patients and public involvement
There was no active patient or public involvement in the 
current study.
results
A total of 147 936 subjects were identified from the CGPL 
database that had a TFT and an ECG recorded within 7 
days of each other between 2001 and 2011. After exclu-
sion, 132 707 subjects (90%) were included for further 
analyses. Of these, 827 (0.6%) had overt hyperthy-
roidism, 1452 (1.1%) had subclinical hyperthyroidism, 
2883 (2.1%) had subclinical hypothyroidism, 336 (0.3%) 
had overt hypothyroidism and 1 27 215 (95.9%) were 
euthyroid. Only 19 (0.01%) subjects had T3 thyrotox-
icosis. The details of the selection process of the study 
cohort are outlined in flow chart (figure 1). The base-
line characteristics of the five groups are presented in the 
table 2. Patients with thyroid disorder were older and less 
often men (24% vs 51%). The distribution of women and 
men in each age group and different thyroid dysfunction 
groups are outlined in a table in supplementary material 
(online supplementary appendix C).
heart rate
The mean heart rate in subjects with both overt 
(87±12 beats/min) and subclinical hyperthyroidism 
(76±14 beats/min) was higher than the mean heart 
rate in euthyroid subjects (70±13 beats/min, figure 2), 
whereas subjects with overt hypothyroidism (68±12 beats/
min) had slower mean heart rate than those with euthy-
roidism. For the association between thyroid dysfunction 
and heart rate, interactions with both age (p=0.009) and 
sex (p<0.001) were identified. Among women, the higher 
Figure 3 Changes in heart rate with thyroid dysfunction by gender and age. Regression plots showing the changes in the 
heart rate (beats/min) with thyroid disorders based on age groups and gender. Euthyroidism is the reference group.
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heart rate for overt hyperthyroidism and lower heart 
rate for overt hypothyroidism were less pronounced for 
patients of higher age (figure 3). Likewise, among men, 
the association between higher heart rate and overt hyper-
thyroidism was less pronounced in patients with higher 
age. Subclinical hyperthyroidism was also associated 
with higher heart rate across all thee age groups among 
women. For men, a similar trend was observed (figure 3).
Qtc interval
In comparison with the euthyroid group (425±24 ms), 
the heart rate corrected QTc interval (QTc Bazett) was 
prolonged in subjects with overt hyperthyroidism (435±22 
ms, p<0.05), subclinical hyperthyroidism (431±24 ms, 
p<0.05) and subclinical hypothyroidism (431±24 ms, 
p<0.05). Significant interactions with both age (p<0.001) 
and sex (p<0.001) were identified. For both sexes, overt 
hyperthyroidism was significantly associated with signifi-
cantly prolonged QTc interval in the young (16–44.6 
years) to middle-age (44.6–60 years) groups but not in 
the oldest subgroup (60–102.7 years; figure 4). Among 
women, overt hypothyroidism was significantly associated 
with a shorter QTc interval in the young to middle-age 
groups, whereas the association was insignificant for the 
oldest age group (figure 4). Among men, however, the 
QTc interval was longer in patients with both subclinical 
and overt hypothyroidism only in the oldest age group 
(figure 4).
low voltage
Among the study groups, both subclinical and overt 
hypothyroidism were associated with low voltage. With 
increasing age, the observed associations were less 
pronounced (p=0.0018 for interaction) (figure 5).
P-wave duration, Pr interval and Qrs duration
In comparison with the P-wave duration in the euthyroid 
group (108.7±12.6 ms), the P-wave duration was shorter 
in patients with overt hyperthyroidism (106.0±12.6 ms, 
figure 2) by an estimate mean duration of −2.2 ms (95% CI 
1.4 to 3.1) in a multiple regression analysis (figure 6). The 
mean PR interval in the overt hypothyroidism (165±25) 
was significantly longer in comparison with the euthyroid 
group (158±23 ms, figure 2) by an estimate mean dura-
tion of 6.61 ms (95% CI 4.30 to 8.92 ms) in a multivariate 
analysis (figure 6). Similarly, subclinical hypothyroidism 
was associated with longer PR interval by 1.5 ms (95% CI 
0.7-2.3 ms). The overt hyperthyroid subjects had a shorter 
QRS duration (88.5±9.6) in comparison with the euthy-
roid (93.5±10.5 ms) subjects (figure 2). However, no 
significant difference was observed in a multivariate anal-
ysis (figure 6).
Figure 4 Changes in QTc interval with thyroid dysfunction by gender and age. Regression plots showing the changes in the 
QTc interval (ms) with thyroid disorders in comparison with the euthyroidism based on age groups and gender.
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Additional analysis
We performed a sensitivity analysis, in which individuals 
with known cardiac comorbidity and concomitant medical 
therapy that might influence the ECG parameters were 
excluded. In this sensitivity analysis, 100 176 individuals 
were included, which corresponds to approximately 75% 
of the total study population. Overall, the results did not 
differ from our main findings (provided in online supple-
mentary appendix D). Additional analyses for the asso-
ciation of TSH levels on heart rate and QTc interval are 
provided in online supplementary appendix E.
DIsCussIOn
This large registry-based study demonstrates associations 
of both overt and subclinical thyroid dysfunction with a 
range of common ECG parameters such as heart rate, 
QTc interval, PR interval, QRS duration, P-wave duration 
and presence of low voltage that verifies some of the find-
ings from previous studies in a larger cohort.10 11 14 15 17 
The most novel finding of the current study is that the 
impact of thyroid dysfunction on heart rate, QTc interval 
and presence of low-voltage is lower with higher patient 
age. Moreover, women have significantly greater changes 
in heart rate and QTc interval than men. These findings 
expand our existing knowledge on ECG changes associ-
ated with thyroid dysfunction.
Most of the previous studies have investigated the rela-
tionship of thyroid dysfunction with QTc interval as both 
prolonged and shorter QTc interval have been associ-
ated with sudden cardiac death and complex ventricular 
arrhythmias.12 23 The general consensus from previous 
smaller studies is that both hyperthyroidism10 16 24 25 and 
hypothyroidism14 15 26 27 are associated with prolongation 
of the QTc interval. In the present study, hyperthyroidism 
was associated with prolonged QTc interval in younger to 
middle-aged subjects among both genders, but the asso-
ciation was weakened with age and was not present for 
older patients. Moreover, hypothyroidism was associated 
with both prolongation and shortening of QTc interval 
depending on the age and gender of the subjects. These 
findings indicate that the effect of thyroid disorder on the 
electrical conduction system of heart varies by gender and 
the thyroid hormonal influence on the heart decreases 
with age.
Previous studies have reported that hyperthyroidism 
is associated with increased heart rate while hypothy-
roidism leads to a slower heart rate.3 Increased heart rate 
has been associated with mortality and cardiovascular 
morbidity.28 29 The present study confirmed previous 
Figure 5 Risk of low voltage with thyroid dysfunction. Forest 
plot showing the risk for low-voltage on ECG with thyroid 
disorders in comparison with the euthyroid reference group 
after adjusting for age and gender. 
Figure 6 Changes in P-wave, PR interval and QRS duration 
according to thyroid dysfunction. Regression plots showing 
the changes in the P-wave duration (ms), PR interval (ms) and 
QRS duration (ms) with thyroid disorder in comparison to the 
euthyroid reference group adjusted for age and gender.
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findings with overall higher and lower heart rates for 
patients with hyperthyroidism and hypothyroidism, 
respectively. In addition, we report that these findings 
differed according to different age groups like QTc 
interval, indicating that the thyroid hormonal influence 
on the heart decreases with age. Furthermore, the effect 
of hypothyroidism on heart rate was limited to women in 
our study.
The present study found an increased risk of low voltage 
in both subclinical and overt hypothyroidism. Although 
previous studies have demonstrated that overt hypothy-
roidism is associated with low voltage,30 our study further 
extends the finding of increased risk of low voltage even 
in patients with subclinical hypothyroidism. This suggests 
that even mild thyroid hormone deficiency can affect the 
QRS voltage amplitude, which might be important given 
the fact that low voltage is associated with increased risk 
of mortality.31 A survey from the USA found that pres-
ence of low voltage on ECG in patients with no history 
of cardiovascular disease was associated with a two-fold 
increased risk of mortality in comparison with those 
without low voltage changes on ECG.31 The current study 
further demonstrates that with increasing age, the like-
lihood of presence of low-voltage on ECG is reduced in 
patients with hypothyroidism.
We consistently found that the influence of thyroid 
dysfunction on ECG changes was less pronounced in 
patients with higher age. One potential explanation 
could be that sensitivity of the electrical conduction 
system of the heart to changes in the thyroid hormone 
level is reduced with age. Another plausible explanation 
is that because of ECG changes due to prevalent age-re-
lated comorbidities, the changes due to thyroid dysfunc-
tion are not evident. This latter explanation is however 
not supported by our sensitivity analysis, in which patients 
with cardiac comorbidities and/or concomitant medical 
therapy that interact with ECG parameters were excluded, 
still the results were consistent with our main findings. 
In addition, our findings are also supported by recent 
studies demonstrating that thyroid dysfunction have 
no impact on cardiovascular outcomes and mortality in 
elderly populations.8 32
In the present study, we observed a shorter P-wave 
duration in hyperthyroidism and a longer PR interval 
in patients with hypothyroidism when adjusted for age, 
gender and heart rate in the adjusted models. Few smaller 
studies have investigated the association of thyroid 
hormones on PR interval and QRS duration with some 
conflicting results.27 33 However, in our study, we did not 
observe any associations between the different thyroid 
conditions and changes in QRS duration. Changes in 
P-wave duration and PR interval have important implica-
tions as demonstrated by Nielsen et al, where both shorter 
and longer P-wave duration34 and PR interval22 were asso-
ciated with increased risk for atrial fibrillation.
The association of TSH on heart rate and QTc interval 
in both sexes is limited to when TSH is depressed but 
not when it is elevated. Moreover, this association is 
predominantly observed among young and middle-aged 
subjects. This is partly in line with the main findings of 
our study observed among hyperthyroid dysfunction 
subgroups. However, changes in ECG parameters are 
not linearly correlated to increase in TSH which is likely 
related to changes in T4 as demonstrated by previous 
studies.10 25
Implications
Cardiomyocytes are well known to be affected by thyroid 
hormones with increased cardiac contractility and 
increased heart rate and risk of proarrhythmic effects.3 
This study from a large real-life cohort presents the 
ECG changes in clinically relevant subgroups of thyroid 
dysfunctions that makes it easier for the study findings to 
apply in routine clinics. Moreover, it attempts to bridge 
the current abundant, but conflicting, knowledge on 
pathophysiological changes in ECG changes with thyroid 
dysfunction. Owing to large study population, it is revealed 
that there is a biological interaction of age and gender 
on the ECG changes associated with thyroid dysfunction. 
This indicates that ECG changes are not universal in each 
subgroup and are rather affected by the age and gender 
of the individual subject. Further research on the physi-
ology behind this interaction will enrich our knowledge 
on the impact of thyroid dysfunction in cardiovascular 
morbidity and mortality. Moreover, the present study 
establishes that subclinical thyroid dysfunctions are also 
associated with important ECG changes that are known 
to be of prognostic importance.12 22 31 34 Further studies 
focusing on the prognostic implication of these ECG 
changes in subclinical thyroid dysfunction would be clin-
ically relevant.
limitations
Despite being a large study cohort, our study has some 
important limitations. Since this is an observational study, 
it is not possible to draw direct conclusions on causality 
regarding the findings. The study patients were referred to 
TFT and an ECG recording by their general practitioner 
based on their discretion, and there were no uniform 
selection criteria for why the patients received these diag-
nostic tests, because of this selection bias cannot be ruled 
out that is, the general practitioners would be prone to 
focus more on tachycardia or bradycardia in patients with 
thyroid dysfunction and therefore order more ECGs in 
these subjects. Because ECGs were recorded ±7 days of 
the TFTs, there is also the risk of reverse causation bias, for 
instance, due to a finding of tachycardia on the ECG, the 
general practitioner decided to refer for TFTs. Addition-
ally, this study did not have access to other clinical param-
eters, such as body mass index, smoking status and blood 
pressure. However, in a sensitivity analysis, exclusion of 
cardiac comorbidity and concomitant medical therapy 
that might influence the ECG pattern did not change the 
conclusions from the main findings. The greater Copen-
hagen area consists mainly of Caucasian people, and for 
that reason, extrapolation to other ethnic groups should 
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be done carefully. Lastly, the size of the sample implies a 
possibility of type I error requiring a careful interpreta-
tion of the results from a clinical point of view.
COnClusIOn
Changes in ECG parameters particularly heart rate, QTc 
duration and low voltage were less pronounced in older 
patients with thyroid dysfunction relative to younger coun-
terparts. Patients with both overt and subclinical thyroid 
dysfunctions were associated with significant changes in 
several ECG parameters including heart rate, QTc dura-
tion, P-wave duration, PR interval and low voltage.
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